This is a speculative early-stage collaboration with no near-term revenue or earnings impact. Monitor for definitive agreements and regulatory milestones; the stock may see short-term volatility on narrative alone, but fundamentals remain unchanged.
Price Chart
Executive Summary
EUDA Health announced a non-binding MOU with GO POSB and SIIT to collaborate on an iPSC-based cell therapy program for oncology and wellness. EUDA will fund the collaboration and facilitate commercialization, but the technologies are investigational and subject to definitive agreements and regulatory approvals. No financial terms or revenue impact were disclosed.
Key Facts
- MOU signed July 15, 2026, with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd.
- EUDA intends to fund the joint collaboration and support global market access for off-the-shelf cell therapies.
- Technologies are under development and investigational; commercial availability depends on funding, testing, and regulatory approvals.
- The MOU is non-binding and subject to execution of definitive agreements.
Financial Impact
No dollar amounts disclosed; EUDA's funding commitment is unspecified.
Risk Factors
- Non-binding MOU may not lead to definitive agreements or successful product development.
- Cell therapy development is capital-intensive and carries high clinical and regulatory risk.
- EUDA's core business is distribution of wellness products, not biotech R&D; execution risk is elevated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (EUDA) — Batch item 1 | 0001493152-26-035546 |
| Document: form6-k.htm | 0001493152-26-035546 |
| Document: 0001493152-26-035546-index-headers.html | 0001493152-26-035546 |
| Document: 0001493152-26-035546-index.html | 0001493152-26-035546 |
| Document: 0001493152-26-035546.txt | 0001493152-26-035546 |
| 6-K Filing (EUDA) — Batch item 6 | 0001493152-26-035546 |
| Document: form6-k.htm | 0001493152-26-035546 |
| Document: 0001493152-26-035546-index-headers.html | 0001493152-26-035546 |
| Document: 0001493152-26-035546-index.html | 0001493152-26-035546 |
| Document: 0001493152-26-035546.txt | 0001493152-26-035546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $17.01 $14.90 | ▲ +12.40% | ▲ +11.25% | $14.46 (+14.99%) |
Oct 13, 2026 13d ago | 6-K | $17.01 $14.90 | ▼ −12.40% | ▼ −11.25% | $14.46 (−14.99%) |
Aug 26, 2026 8w ago | Press Release | $14.10 $13.84 | ▼ −1.84% | ▼ −1.72% | $14.46 (+2.55%) |
Aug 11, 2026 11w ago | EFFECT | $15.23 $14.49 | ▲ +4.87% | ▲ +4.47% | $14.46 (+5.06%) |
Jul 31, 2026 12w ago | 6-K | $19.30 $15.90 | ▼ −17.62% | ▼ −21.13% | $14.46 (−25.08%) |
Jul 22, 2026 13w ago | 424B5 | $14.00 $20.35 | ▲ +45.36% | ▲ +47.76% | $14.46 (+3.29%) |
Jun 11, 2026 19w ago | 424B5 | $15.02 $16.49 | ▲ +9.79% | ▲ +9.35% | $14.46 (−3.73%) |
Apr 28, 2026 25w ago | Press Release | $12.00 $16.31 | ▲ +35.92% | ▲ +34.22% | $14.46 (+20.50%) |
Mar 19, 2026 31w ago | Press Release | $7.98 $11.44 | ▲ +43.36% | ▲ +45.57% | $14.46 (+81.20%) |
Mar 4, 2026 33w ago | Press Release | $15.74 $10.04 | ▼ −36.21% | ▼ −34.88% | $14.46 (−8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers